Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits

Neuropsychopharmacology

Volumn 39, Issue 7, 2014, Pages 1603-1613

  Billingslea, Eddie N ^a   Tatard Leitman, Valerie M ^a   Anguiano, Jaynie ^a   Jutzeler, Catherine R ^a   Suh, Jimmy ^a   Saunders, John A ^a   Morita, Susumu ^a   Featherstone, Robert E ^a   Ortinski, Pavel I ^a   Gandal, Michael J ^a   Lin, Robert ^a   Liang, Yuling ^a   Gur, Raquel E ^a   Carlson, Gregory C ^a   Hahn, Chang Gyu ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; BACLOFEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PARVALBUMIN; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; GPRIN1 PROTEIN, MOUSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE PROTEIN; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC SYSTEM; IMMUNOHISTOCHEMISTRY; INTERNEURON; LONG TERM POTENTIATION; MOUSE; NEGATIVE SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RESTING NETWORK EXCITABILITY; RESTING STATE NETWORK; SCHIZOPHRENIA; SELF CARE; SOCIAL BEHAVIOR; SOCIAL CARE; SOCIAL STATUS; ANIMAL; ANTISOCIAL PERSONALITY DISORDER; BRAIN; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EVOKED RESPONSE; EXPLORATORY BEHAVIOR; GENETICS; HUMAN RELATION; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; REST; TRANSGENIC MOUSE;

ANIMALS; BACLOFEN; BRAIN; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; GABA AGONISTS; INTERPERSONAL RELATIONS; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; PARVALBUMINS; PYRIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; REST; SELF CARE; SOCIAL BEHAVIOR DISORDERS;

EID: 84900562296     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.7     Document Type: Article

References (42)

1. Amann LC, Halene TB, Ehrlichman RS, Luminais SN, Ma N, Abel T et al (2009). Chronic ketamine impairs fear conditioning and produces long-lasti ng reductions in auditory evoked potentials. Neurobiol Dis 35: 311-317.
2. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E et al (2000). Assessment in multisite randomize d clinical trials of patients with autistic disorDer: The Autism RUPP Network. Research Units on Pediatric Psychopharmacology. J Autism Dev Disord 30: 99-111.
3. Belforte JE, Zs iros V, Sklar ER, Jiang Z, Yu G, Li Y et al (2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13: 76-83.
4. Boutros NN, Broc khaus-Dumke A, Gjini K, VeDeniapin A, Elfakhani M, Burroughs S et al (2009). Sensory-gating Deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 113: 339 -346.
5. Burket JA, Herndon AL, Winebarger EE, Jacome LF, Deutsch SI (2011). Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacotherapy of autism spe ctrum disorDers. Brain Res Bull 86: 152-158.
6. Capecchi MR (1989). Altering the genome by homologous recombination. Science 244: 1288-1292.
7. Carlen M, Meletis K, Siegle JH, Cardin JA, Futai K, Vierling-Claassen D et al (2012). A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 17: 537-548.
8. Carlson GC, Talbot K, Halene TB, Gandal MJ, Kazi HA, Schlosser L et al (2011). Dysbindin-1 mutant mice implicate reduced fastphasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci USA 108: E962-E970.
9. Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T et al (2004). The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory E RP components. Neurochem Res 29: 1179-1188.
10. Deacon RM (2006). Assessing nest building in mice. Nat Protoc 1: 1117-1119.
11. Deacon RM, Rawlins JN (2006). T-maze alternation in the roDent. Nat Protoc 1: 7-12.
12. Delorme A, Makeig S (2004). EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including inDepenDent component analysis. J Neurosci Methods 134: 9-21.
13. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D et al (2009). N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological Deficits in schizophrenia. Neuroscience 158: 705-712.
14. Ehrlichman RS, Maxwell CR, Majumdar S, Siegel SJ (2008). Deviance-elicited changes in event-related potentials are attenuate d by ketamine in mice. J Cogn Neurosci 20: 1403-1414.
15. Featherstone RE, Liang Y, SaunDers JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ (2012). Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 47: 338-346.
16. Featherstone RE, MT-L V, Suh JD, Lin R, Lucki I, Siegel SJ (2013). Electrophysiological and behavioral r esponses to ketamine in mice with reduced Akt1 expression. Psychopharmacology (Berl) 227: 639-649.
17. Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ (2010). Validating gamma oscillations and Delayed auditory responses as translational biomarkers of autism. Biol Psychiatry 68: 1100-1106.
18. Gandal MJ, Ehrlichman RS, Rudnick ND, Siegel SJ (2008). A novel electrophysiological moDel of chemotherapy-induced cognitive impairments in mice. Neuroscience 157: 95-104.
19. Gandal MJSJ, Klook K, Tatard-Leitman VM, Liang Y, Thieu T, Ortinski PI et al (2012). GABAB-mediated rescue of altered exc itatory-inhibitory balance, gamma synchrony, and behavioral Deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2: E142.
20. Gur RC, Ragland JD, Moberg PJ, Bilker WB, Kohler C, Siegel SJ et al (2001). Computerized neurocognitive scanning: II. The profile of schizophrenia Neuropsychopharmacology 25 777-788.
21. Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL et al (2009). Assessment of NMDA receptor NR1 subunit hypofunction in mice as a moDel for schizophrenia. Genes Brain Behav 8: 661-6 75.
22. Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR et al (2005). A Developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol 3: E159.
23. Hugdahl K, Loberg EM, Nygard M (2009). Left temporal lobe structural and functional abnormality unDerlying auditory hallucinations in schizophrenia. Front Neurosci 3: 34-45.
24. Javi tt DC, Zylberman I, Zukin SR, Heresco-Levy U, LinDenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234-1236.
25. Krystal JH, Karper LP, Sei byl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
26. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
27. Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, Siegel SJ (2010). Ketamine modulates theta and gamma oscillations. J Cogn Neurosci 22: 1452-1464.
28. Maxwell CR, Ehrlichman RS, Liang Y, Tri ef D, Kanes SJ, Karp J et al (2006). Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther 316: 315-324.
29. Mehta MV, Gandal MJ, Siegel SJ (2011). mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA moDel of autism. PLoS One 6: E26077.
30. Pacey LK, Heximer SP, Hampson DR (2009). Increased GABA(B) receptor-mediated signali ng reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76: 18-24.
31. Roberts TP, Khan SY, Rey M, Monroe JF, Cannon K, Blaskey L et al (2010). MEG Detection o f Delayed auditory evoked responses in autism spectrum disorDers: Towards an imaging biomarker for autism. Autism Res 3: 8-18.
32. Sankoorikal GM, Kaercher KA, Boon CJ, Lee JK, Brodkin ES (2006). A mous e moDel system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry 59: 415-423.
33. SaunDers JA, Gandal MJ, Roberts TP, Siegel SJ (2012). NMDA antagonist MK801 rec reates auditory electrophysiology disruption present in autism and other neuroDevelopmental disorDers. Behav Brain Res 234: 233-237.
34. SaunDers JA, Tatard-Leitman VM, Suh J, Billingslea EN, Roberts TP, Sie gel SJ (2013). Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes. Autism Res 6: 69-77.
35. Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD et al (2006). Prognostic variables at intake and long-term level of function in schizophrenia. Am J Psychiatry 163: 433-441.
36. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS et al (2012). Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social Deficits in mouse moDels of autism. Sci Transl Med 4: 131ra151.
37. Silverman JL, Tolu SS, Barkan CL, Crawley JN (2010). Repetitive self-grooming behavior in the BTBR mouse moDel of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35: 976-989.
38. Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, AnDerson DJ et al (1996). Subregion-and cell type-restricted gene knockout in mouse brain. Cell 87: 1317-1326.
39. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, CaDenhead KS et al (2008). Abnormal auditory N100 amplituDe: A heritable endophenotype in first-Degree relatives of schizophrenia probands. Biol Psychiat ry 64: 1051-1059.
40. Van Balkom ID, Vuijk PJ, Franssens M, Hoek HW, Hennekam RC (2012). Development, cognition, and behaviour in Pitt-Hopkins syndrome. Dev Med Child Neurol 54: 925-931.
41. Winterer G,Ziller M,Dorn H,Frick K,Mulert C,Wuebben Y,et al, 2000, Schizophrenia: Reduced signal-to-noise ratio and impaired phase-locking during information processing, Clin Neurophysiol, 111: 837-849.
42. Yizhar O, Fenno LE, Prigge M, SchneiDer F, Davidson TJ, OShea DJ et al (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477: 171-178.